Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control
Key facts
- Who runs it
- Ruihua Wei
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 410 people, planned
- Started
- 1 Feb 2024
- Planned end
- 31 Mar 2026
- Type of study
- Interventional, 5 groups
- Treatments tested
- DIMS
- The 0.02% ATP Group
- The 0.04% ATP Group
- 0.02%ATP+DIMS
- 0.04%ATP+DIMS
- Record updated
- 8 September 2025
Who can take part
- Age
- 6 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- School-age children aged 6 to 12 years (including boundary value)
- Children with moderate or high myopia (subjective refraction after cycloplegia: -9.00D≤spherical equivalent (SE)≤-3.00D, with-rule astigmatism (C)≤2.00D, against-rule astigmatism (C)≤1.00D, anisometropia of both eyes≤2.50D)
- Binocular best corrected visual acuity (BCVA)≥0.8 (five-point visual acuity 4.9)
- Agree with the study scheme and sign the informed consent
- Note: if both eyes meet the inclusion criteria, the eye with higher spherical equivalent is the study eye; if one eye meets the inclusion criteria, the eye is the study eye
Who cannot take part
- Used or currently using orthokeratology, multifocal contact lenses, defocusing framework lenses, atropine eye drops and other myopia control means in the past month; used red light treatment in the past
- Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
- With congenital eye disease, such as congenital cataract, congenital retinal disease
- Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
- Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
- Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
- Children with obvious strabismus and amblyopia
- Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP \>21mmHg or binocular IOP difference ≥5mmHg)
- Optic nerve damage or congenital optic nerve dysfunction
- Can not be regularly checked
- The adjustment range is less than 8D or obvious near difficulties
- Other reasons researchers think it is not suitable for inclusion in researchers
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 6 and 12 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.
The 5 groups in the trial
- The DIMS GroupTreatment being tested
wear DIMS ,and use placebo,once nightly, both eye
Treatment: DIMS
- 0.02% ATPTreatment being tested
wear SP, and use 0.02%ATP eye drops, once nightly, both eye
Treatment: The 0.02% ATP Group
- 0.04%ATPTreatment being tested
wear SP, and use 0.04%ATP eye drops, once nightly, both eye
Treatment: The 0.04% ATP Group
- 0.02%ATP+DIMSTreatment being tested
wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
- 0.04%ATP+DIMSTreatment being tested
wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Low-concentration Atropine Eye Drops (0.02%, 0.04%) Combined With Defocus Incorporated Multiple Segments (DIMS) for Moderate and High Myopia Control
- Criteria questions
- Built from NCT06523504, who can take part
- Record updated
- 8 September 2025